EDIT stock forecast, quote, news & analysis
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases... Show more
Why Is Editas Medicine, Inc. (EDIT) Stock Down -14.52% Today?
Key Takeaways
- EDIT shares fell approximately 14.52% as of the latest available price, closing the prior session at $3.34.
- The primary catalyst was investor reaction to the company’s recent public stock offering announcement, raising dilution concerns.
- Secondary factors include broader biotech sector weakness and typical volatility in clinical-stage gene-editing names.
- Trading volume ran above average, reflecting heightened selling pressure amid the capital raise.
- Traders are monitoring upcoming pipeline updates and any additional financing activity.
Opening Summary
Editas Medicine, Inc. (EDIT) is a clinical-stage biotechnology company developing CRISPR-based gene editing therapies for serious diseases, including its lead program targeting hyperlipidemia. Shares declined sharply, dropping 14.52% from the previous close of $3.34. The move reflects market reaction to the company’s announcement of a sizable public offering of common stock and pre-funded warrants, which raised concerns over share dilution for existing investors.
Stock Offering and Dilution Concerns
On May 26, Editas announced a proposed public offering and subsequently priced it for up to approximately $319.4 million. Such capital raises are common for development-stage biotechs needing funds to advance clinical programs, yet they often trigger immediate selling as investors factor in the increased share count and potential downward pressure on the stock price. The offering weighed on sentiment despite earlier positive preclinical data for EDIT-401.
Market Context and Trading Activity
Volume surged well above the recent average, indicating broad participation in the sell-off. The decline occurred against a mixed backdrop for the broader biotechnology sector, where small-cap names frequently experience amplified moves on company-specific news. EDIT broke below recent support levels near $3.30, aligning with technical selling as stop-loss orders triggered. The move diverged from major indices, underscoring the stock-specific nature of the reaction.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with only the top performers featured in this curated section. Bots differ by strategy, timeframe, performance metrics, and traded symbols. Visit the page to explore active strategies that may complement your research.
What Comes Next for EDIT
Investors will watch for further details on the use of proceeds from the offering and any updates on the company’s clinical pipeline, including EDIT-401 development. Key risks remain centered on clinical trial outcomes, regulatory pathways, and ongoing cash burn typical of early-stage biotech firms. No immediate earnings date is highlighted in the near term, keeping focus on execution milestones and potential partnership news.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsEDIT's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for EDIT moved out of overbought territory on May 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on June 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
EDIT moved below its 50-day moving average on June 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EDIT crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EDIT broke above its upper Bollinger Band on May 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (86.957) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). EDIT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (5.974) is also within normal values, averaging (357.550).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology